Biogen Inc (BIIB)

$216.63 +0.60 (0.28%)
Market Cap 31.89B
Revenue (ttm) 9.89B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 13.64
Forward PE 14.48
Profit Margin 13.07%
Debt to Equity Ratio 0.34
Volume 1,279,700
Avg Vol 1,161,306
Day's Range N/A - N/A
Shares Out 147.64M
Stochastic %K 92%
Beta 0.20
Analysts Strong Sell
Price Target $220.00

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
Cad_Bane
Cad_Bane Jun. 29 at 9:12 PM
$BIIB so they bought another turd and waited until after they bought it to evaluate it - sounds like Biogen🤣🤣🤣🤣
0 · Reply
OldManLogan
OldManLogan Jun. 29 at 4:36 PM
$LRMR Reata was sold to $BIIB for $7.3B even though Skyclarys was aimed at helping patients deal with the inflammation and oxidative stress from the disease progression whereas Larimar's drug essentially replaces the protein in the body that causes the disease in the first place... I have to believe that LRMR is worth a tad more than $300M a year out from first sales, lol.
0 · Reply
prismmarketview
prismmarketview Jun. 29 at 4:02 PM
$BIIB will highlight its Alzheimer’s portfolio at AAIC 2026, including full Phase 2 CELIA readout for diranersen (BIIB080), an antisense therapy aimed at tau. Primary endpoint missed, but biomarker + efficacy signals look strong enough for next‑step planning. #BIIB #Alzheimers #tau #neurodegeneration https://prismmarketview.com/biogen-puts-alzheimers-pipeline-in-the-spotlight-with-new-diranersen-phase-2-data/
0 · Reply
ZacksResearch
ZacksResearch Jun. 29 at 1:31 PM
"Biotech is on fire 🔥 But which names are driving the rally? $LLY, $ABBV, $JNJ and $BIIB all hit fresh 52-week highs as strong pipeline progress, regulatory wins, approvals and M&A activity fueled growing confidence across the biotech sector. 📈 Latest LLY news here👉 " https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-38568&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38568
0 · Reply
clairelong37
clairelong37 Jun. 29 at 8:15 AM
$BIIB large bio lag watch, needs demand before trend talk matters
0 · Reply
FloridaMenace
FloridaMenace Jun. 27 at 12:09 AM
$BIIB The BiiB crushed it today . 240.00s next week !!!!
0 · Reply
nottoday800
nottoday800 Jun. 26 at 8:42 PM
$BIIB buyout coming ??
0 · Reply
Bates333
Bates333 Jun. 26 at 8:33 PM
$BIIB bingo
0 · Reply
JFDI
JFDI Jun. 26 at 2:04 PM
$BIIB back from the dead. welcome back to watch list
0 · Reply
WallStJesus
WallStJesus Jun. 26 at 2:02 PM
$BIIB REPEAT BET
0 · Reply
Latest News on BIIB
Biogen price target raised to $256 from $255 at Needham

2026-06-29T12:11:21.000Z - 11 hours ago

Biogen price target raised to $256 from $255 at Needham

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Jun 29, 2026, 6:59 AM EDT - 12 hours ago

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

Jun 26, 2026, 9:25 AM EDT - 3 days ago

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

APLS

Biogen price target raised to $224 from $206 at Morgan Stanley

2026-06-18T10:45:38.000Z - 11 days ago

Biogen price target raised to $224 from $206 at Morgan Stanley

M&A News: Biogen to Acquire RayThera for Up to $1B, Expanding Drug Pipeline

2026-06-18T06:54:17.000Z - 11 days ago

M&A News: Biogen to Acquire RayThera for Up to $1B, Expanding Drug Pipeline

Biogen to acquire RayThera for $1 billion

Jun 17, 2026, 7:10 PM EDT - 12 days ago

Biogen to acquire RayThera for $1 billion

Biogen to acquire RayThera for up to $1B

2026-06-17T23:05:09.000Z - 12 days ago

Biogen to acquire RayThera for up to $1B

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Jun 17, 2026, 6:59 PM EDT - 12 days ago

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 12 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Biogen price target lowered to $221 from $236 at Mizuho

2026-06-15T11:06:03.000Z - 14 days ago

Biogen price target lowered to $221 from $236 at Mizuho

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 20 days ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY CVS PFE VZ

Biogen Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 20 days ago

Biogen Transcript: AGM 2026

Needham upgrades Biogen on pipeline potential, stabilizing core business

2026-06-08T10:52:55.000Z - 21 days ago

Needham upgrades Biogen on pipeline potential, stabilizing core business

Biogen upgraded to Buy from Hold at Needham

2026-06-08T10:36:45.000Z - 21 days ago

Biogen upgraded to Buy from Hold at Needham

Biogen granted Breakthrough Therapy Designation for salanersen by FDA

2026-06-04T11:35:56.000Z - 25 days ago

Biogen granted Breakthrough Therapy Designation for salanersen by FDA

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Jun 4, 2026, 7:30 AM EDT - 25 days ago

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

UCB, Biogen announce dapirolizumab pegol data at EULAR

2026-06-04T09:40:10.000Z - 25 days ago

UCB, Biogen announce dapirolizumab pegol data at EULAR

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Jun 4, 2026, 1:00 AM EDT - 25 days ago

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Jun 3, 2026, 7:30 AM EDT - 26 days ago

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 26 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

ABBV LLY ROP

Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet

2026-06-01T09:55:43.000Z - 4 weeks ago

Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Jun 1, 2026, 1:30 AM EDT - 4 weeks ago

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Biogen price target raised to $227 from $222 at RBC Capital

2026-05-27T13:53:16.000Z - 4 weeks ago

Biogen price target raised to $227 from $222 at RBC Capital

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

May 27, 2026, 2:27 AM EDT - 4 weeks ago

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

May 21, 2026, 6:17 PM EDT - 5 weeks ago

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

2026-05-21T22:05:12.000Z - 5 weeks ago

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

DNLI

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

May 21, 2026, 6:00 PM EDT - 5 weeks ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

Biogen resumed with an Outperform at Evercore ISI

2026-05-15T12:57:10.000Z - 6 weeks ago

Biogen resumed with an Outperform at Evercore ISI

Biogen price target raised to $225 from $214 at Piper Sandler

2026-05-15T10:43:43.000Z - 6 weeks ago

Biogen price target raised to $225 from $214 at Piper Sandler

Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright

2026-05-14T19:18:29.000Z - 6 weeks ago

Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright

ALEC DNLI DYN PRTA

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

May 14, 2026, 12:10 PM EDT - 6 weeks ago

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

May 14, 2026, 9:07 AM EDT - 6 weeks ago

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

Biogen Completes Acquisition of Apellis Pharmaceuticals

May 14, 2026, 8:35 AM EDT - 6 weeks ago

Biogen Completes Acquisition of Apellis Pharmaceuticals

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

May 14, 2026, 7:03 AM EDT - 6 weeks ago

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

May 14, 2026, 6:59 AM EDT - 6 weeks ago

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

Biogen Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 6 weeks ago

Biogen Transcript: Bank of America Global Healthcare Conference 2026

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

May 8, 2026, 2:30 AM EDT - 7 weeks ago

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

May 7, 2026, 6:01 PM EDT - 7 weeks ago

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

APLS BFAM RELY TPH

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026, 4:01 PM EDT - 7 weeks ago

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

STOK

Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Earnings Call Transcript: Q1 2026

Biogen Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Slides: Q1 2026

Biogen Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Earnings release: Q1 2026

Biogen Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Quarterly report: Q1 2026

Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 7:02 AM EDT - 2 months ago

Biogen Lowers 2026 Earnings Outlook

Biogen cuts annual profit forecast on acquisition-related charges

Apr 29, 2026, 6:07 AM EDT - 2 months ago

Biogen cuts annual profit forecast on acquisition-related charges

Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Biogen Proxy statement: Proxy filing

Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Biogen Proxy statement: Proxy filing

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Apr 20, 2026, 9:02 AM EDT - 2 months ago

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Apr 20, 2026, 7:30 AM EDT - 2 months ago

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

Apr 18, 2026, 9:00 AM EDT - 2 months ago

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

LLY

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Apr 7, 2026, 6:00 AM EDT - 2 months ago

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Why This Pharma Stock More Than Doubled Today

Mar 31, 2026, 9:41 AM EDT - 3 months ago

Why This Pharma Stock More Than Doubled Today

APLS

Biogen Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Transcript: M&A announcement

Biogen Press release: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Press release: M&A announcement

Biogen Slides: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Slides: M&A announcement

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

Mar 31, 2026, 8:07 AM EDT - 3 months ago

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

APLS

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Mar 31, 2026, 7:44 AM EDT - 3 months ago

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

APLS

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

Mar 31, 2026, 7:05 AM EDT - 3 months ago

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

APLS

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Mar 31, 2026, 6:59 AM EDT - 3 months ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLS

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

Mar 31, 2026, 6:59 AM EDT - 3 months ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

APLS

US FDA approves higher-dose of Biogen's genetic disorder drug

Mar 30, 2026, 7:36 AM EDT - 3 months ago

US FDA approves higher-dose of Biogen's genetic disorder drug

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Mar 30, 2026, 7:30 AM EDT - 3 months ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

IONS

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Mar 28, 2026, 3:00 PM EDT - 3 months ago

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Mar 20, 2026, 12:05 PM EDT - 3 months ago

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Mar 19, 2026, 7:30 AM EDT - 3 months ago

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Cad_Bane
Cad_Bane Jun. 29 at 9:12 PM
$BIIB so they bought another turd and waited until after they bought it to evaluate it - sounds like Biogen🤣🤣🤣🤣
0 · Reply
OldManLogan
OldManLogan Jun. 29 at 4:36 PM
$LRMR Reata was sold to $BIIB for $7.3B even though Skyclarys was aimed at helping patients deal with the inflammation and oxidative stress from the disease progression whereas Larimar's drug essentially replaces the protein in the body that causes the disease in the first place... I have to believe that LRMR is worth a tad more than $300M a year out from first sales, lol.
0 · Reply
prismmarketview
prismmarketview Jun. 29 at 4:02 PM
$BIIB will highlight its Alzheimer’s portfolio at AAIC 2026, including full Phase 2 CELIA readout for diranersen (BIIB080), an antisense therapy aimed at tau. Primary endpoint missed, but biomarker + efficacy signals look strong enough for next‑step planning. #BIIB #Alzheimers #tau #neurodegeneration https://prismmarketview.com/biogen-puts-alzheimers-pipeline-in-the-spotlight-with-new-diranersen-phase-2-data/
0 · Reply
ZacksResearch
ZacksResearch Jun. 29 at 1:31 PM
"Biotech is on fire 🔥 But which names are driving the rally? $LLY, $ABBV, $JNJ and $BIIB all hit fresh 52-week highs as strong pipeline progress, regulatory wins, approvals and M&A activity fueled growing confidence across the biotech sector. 📈 Latest LLY news here👉 " https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-38568&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38568
0 · Reply
clairelong37
clairelong37 Jun. 29 at 8:15 AM
$BIIB large bio lag watch, needs demand before trend talk matters
0 · Reply
FloridaMenace
FloridaMenace Jun. 27 at 12:09 AM
$BIIB The BiiB crushed it today . 240.00s next week !!!!
0 · Reply
nottoday800
nottoday800 Jun. 26 at 8:42 PM
$BIIB buyout coming ??
0 · Reply
Bates333
Bates333 Jun. 26 at 8:33 PM
$BIIB bingo
0 · Reply
JFDI
JFDI Jun. 26 at 2:04 PM
$BIIB back from the dead. welcome back to watch list
0 · Reply
WallStJesus
WallStJesus Jun. 26 at 2:02 PM
$BIIB REPEAT BET
0 · Reply
BearBonsai
BearBonsai Jun. 25 at 4:40 PM
$BIIB treated me okay
0 · Reply
biotech
biotech Jun. 25 at 4:24 PM
$SGMO $SGMO The Bidding War: $LLY vs. Genentech/ $RHHBY Roche If $BIIB data in July proves that stopping tau is the holy grail for curing Alzheimer's these giant companies will look at Sangamo’s safe permanent "Zinc Finger" switch and realize they need to buy it ad then STAC-BBB
0 · Reply
WallStJesus
WallStJesus Jun. 25 at 3:03 PM
$BIIB BULL BET
0 · Reply
BreakoutsHappen
BreakoutsHappen Jun. 25 at 5:16 AM
Dear Trader, Introducing Smart Money Scanner: our advanced scanner identifies stocks with strong institutional setups through a proprietary 0–100 score that combines fundamentals and technicals. Trend, RSI, volume, and earnings surprises-all in one view.$AAL $AIG $BIIB https://breakoutshappen.com/scanners/smart-money
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 24 at 7:22 PM
$BIIB Current Stock Price: $201.17 Contracts to trade: $200.0 BIIB Jun 26 2026 Call Entry: $2.35 Exit: $3.65 ROI: 55% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
AlphaTrader8
AlphaTrader8 Jun. 24 at 6:18 PM
$MRNA Big Up Move Coming Likely Very Soon $XBI $BIIB $AMGN $SPY
0 · Reply
AlphaTrader8
AlphaTrader8 Jun. 23 at 10:35 PM
$MRNA last chance shorts to scramble and run for the hills cause you’re gonna get toasted $ABBV $XBI $BIIB Bullishness $SPY
0 · Reply
AlphaTrader8
AlphaTrader8 Jun. 23 at 4:41 AM
$MRNA Consolidation and Move Higher Intact Despite today’s downside consolidation, the broader biotech sector continues to strengthen. Historically, $MRNA has tended to move with biotech peers and the sector as a whole. If $AMGN, $BIIB, and $XBI continue higher, $MRNA could follow as sector momentum remains constructive. $AMGN $BIIB $XBI $MRNA $SPY BEARISH
0 · Reply
gazza75799
gazza75799 Jun. 22 at 8:35 PM
$BIIB 200 super resistance. Is it ready to break?
0 · Reply
NetworkNewsWire
NetworkNewsWire Jun. 22 at 3:48 PM
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis $QNTM QNTM.CN $SNY $RHHBY $BIIB $CLNN https://ibn.fm/cVNcf
1 · Reply
NolAsrtormZ
NolAsrtormZ Jun. 20 at 10:53 PM
$SPY Honestly Trump could be the president that cracks the Alzheimers code w phase 3 Alzheimers $ANVS data trading at below $2.00 a share. $BIIB got paid out 14 billion in market cap for brain bleeds
0 · Reply
notreload_ai
notreload_ai Jun. 18 at 10:11 AM
$BIIB is acquiring San Diego biotech RayThera for up to $1 billion, with most payment tied to clinical milestones. https://notreload.xyz/xy/biogen-acquires-raythera-for-up-to-1b/
0 · Reply